antimalari
drug
chemotherapi
agent
use
treatment
malaria
includ
drug
chloroquin
mefloquin
halofantrin
review
focus
chloroquin
hydroxychloroquin
quinacrin
also
known
quinacrin
synthet
drug
develop
becam
main
antimalari
agent
use
alli
world
war
ii
chloroquin
develop
replac
quinin
hydroxychloroquin
deriv
chloroquin
beta
hydroxyl
first
synthes
despit
posit
report
success
use
older
antimalari
drug
treatment
chronic
discoid
lupu
erythematosu
dle
use
antimalari
wide
acknowledg
treatment
seri
use
quinacrin
publish
treat
dle
patient
improv
sinc
substanc
also
success
use
treat
inflammatori
diseas
use
restrict
howev
malaria
rheumatoid
arthriti
system
lupu
erythematosu
yet
recent
decad
dermatolog
particular
antimalari
agent
use
success
treat
number
diseas
new
use
continu
found
even
today
major
studi
drug
perform
decad
ago
thu
current
clinic
studi
use
modern
criteria
larg
unavail
due
lack
interest
evid
effect
lack
financi
incent
unlik
studi
perform
time
soon
current
knowledg
thu
often
base
open
studi
patient
seri
case
report
present
review
tri
test
safe
use
correctli
drug
well
indic
present
follow
inform
appli
equal
adult
adolesc
children
chloroquin
mg
chloroquin
diphosph
mg
ca
diphosph
cq
figur
pure
white
crystallin
powder
hydroxychloroquin
hcq
deriv
chloroquin
ca
figur
two
substanc
differ
regard
mechan
action
pharmacokinet
toxicolog
side
effect
indic
follow
inform
appli
drug
recommend
dosag
base
clinic
relev
inform
salt
ie
chloroquin
diphosph
hydroxychloroquin
sulfat
respect
base
complex
mechan
action
chloroquinehydroxychloroquin
cqhcq
discuss
detail
elsewher
drug
effect
better
explain
variou
factor
singl
one
alon
tabl
cqhcq
antiprolif
properti
allevi
inflamm
inhibit
thrombocyt
aggreg
enhanc
glucos
toler
caus
increas
porphyrin
excret
effect
make
substanc
use
therapi
import
effect
result
lysosomotrop
properti
cqhcq
discuss
greater
detail
cqhcq
amphiphil
molecul
lipophil
ring
structur
hydrophil
side
chain
figur
thu
tend
deposit
interphas
instanc
phospholipid
membran
weakli
basic
molecul
pass
membran
proton
acid
milieu
cytoplasm
posit
load
molecul
cqhcq
lose
abil
pass
membran
thu
accumul
factor
primarili
macrophag
lysosom
plasmodium
parasit
caus
malaria
intralysosom
proteas
thu
inhibit
lead
heme
accumul
toxic
parasit
human
leukocyt
lysosom
accumul
antigen
peptid
major
histocompat
complex
well
stimul
receptor
inhibit
process
autoantigen
particular
diminish
thu
also
decreas
subsequ
immunolog
effect
tabl
indirect
effect
cell
enabl
agent
well
combin
immunomodulatori
drug
delay
clinic
effect
may
explain
fact
primarili
affect
cell
quinacrin
yellow
acridin
dye
ca
number
mepacrin
quinacrin
dihydrochlorid
longer
commerci
avail
may
order
pharmaceut
distributor
heinz
germani
http
wwwpharmavertriebheinzed
obtain
drug
england
bcm
special
http
wwwbcmspecialscouk
cqhcq
taken
oral
quickli
almost
complet
absorb
bioavail
tablet
taken
togeth
meal
cqhcq
better
absorb
empti
stomach
follow
meal
maximum
plasma
level
reach
within
hour
mepacrin
also
quickli
thoroughli
absorb
maximum
plasma
level
achiev
hour
percent
chloroquin
bound
plasma
protein
cqhcq
accumul
thrombocyt
granulocyt
erythrocyt
concentr
whole
blood
time
higher
plasma
mani
intern
organ
concentr
cqhcq
much
time
greater
blood
due
high
affin
chloroquin
melanin
highest
concentr
found
eye
skin
concentr
time
higher
plasma
epidermi
time
higher
dermi
greatest
concentr
found
spleen
follow
liver
kidney
lung
heart
muscl
brain
virtual
accumul
chloroquin
adipos
tissu
due
accumul
deep
compart
fictiti
distribut
volum
high
lkg
take
least
week
chloroquin
month
hydroxychloroquin
reach
equilibrium
appli
quinacrin
accumul
organ
cqhcq
equilibrium
achiev
week
percent
bound
plasma
protein
cqhcq
slowli
elimin
plasma
concentr
drop
exponenti
word
concentr
decreas
rapidli
first
gradual
depend
dosag
exponenti
decreas
drug
rang
hour
day
control
complianc
plasma
level
hcq
cq
concentr
hair
may
measur
quinacrin
elimin
slowli
kidney
discontinu
drug
signific
urin
level
still
detect
month
cq
elimin
unalt
urin
renal
impair
thu
significantli
prolong
drug
cq
low
level
hcq
caus
reduct
creatinin
clearanc
especi
older
patient
slow
cq
excret
given
cq
accumul
risk
side
effect
higher
patient
thu
dosag
reduc
accordingli
cq
metabol
cytochrom
liver
pharmacolog
activ
metabolit
cq
excret
stool
drug
plasma
level
depend
less
elimin
revers
diffus
agent
deep
compart
plasma
studi
report
follow
singl
dose
trace
cq
persist
plasma
erythrocyt
day
regim
still
trace
month
skin
plasma
therapi
continu
found
plasma
erythrocyt
urin
year
last
dose
relationship
cq
precis
defin
hcq
low
plasma
concentr
ngml
reportedli
exacerb
system
le
higher
plasma
concentr
associ
increas
risk
advers
effect
therapi
well
acut
intox
advers
effect
avoid
observ
maximum
daili
dosag
fear
complic
antimalari
drug
irrevers
retinopathi
depend
neither
treatment
durat
cumul
overal
dose
rather
whether
maximum
daili
dosag
base
ideal
bodi
weight
exceed
maximum
daili
dosag
mgkg
ideal
bodi
weight
chloroquin
mgkg
ideal
bodi
weight
hydroxychloroquin
maximum
dosag
observ
retinopathi
concern
even
therapi
last
sever
year
studi
patient
averag
length
treatment
year
cumul
dose
g
retinopathi
occur
daili
dosag
mgkg
chloroquin
mgkg
hydroxychloroquin
nevertheless
product
inform
provid
advis
adult
cumul
dosag
exceed
g
chloroquin
per
kg
bodi
weight
g
total
dose
everyday
clinic
practic
given
cqhcq
store
adipos
tissu
dosag
may
adjust
accord
patient
ideal
bodi
weight
men
height
cm
women
height
cm
patient
actual
weight
ideal
dosag
adjust
accord
actual
weight
avoid
retinopathi
maximum
daili
dosag
mgkg
chloroquin
mgkg
hydroxychloroquin
exceed
longer
period
time
administr
higher
daili
dosag
problem
may
necessari
instanc
give
initi
higher
dosag
day
rapidli
reach
therapeut
blood
level
import
note
increas
side
effect
possibl
misunderstand
prescrib
hcq
tablet
divid
tabl
patient
ideal
bodi
weight
kg
given
cq
tablet
per
day
mg
maximum
dosag
thu
mgkg
ideal
bodi
weight
patient
ideal
weight
kg
would
given
dosag
mgkg
bodi
weight
chloroquin
heavier
weight
administr
tablet
per
day
unproblemat
tabl
caution
exercis
treat
patient
actual
ideal
bodi
weight
less
kg
appli
especi
smaller
lighter
patient
particular
women
shorter
heavier
patient
patient
even
singl
tablet
usual
dosag
mg
cq
mg
hcq
equival
dosag
given
prolong
period
time
much
kidney
liver
function
impair
dosag
must
decreas
quinacrin
administ
oral
avoid
advers
effect
dosag
exceed
mgdaili
tablet
optim
effect
achiev
month
dosag
reduc
everi
one
tablet
week
everi
month
mainten
dose
tabletsweek
reach
patient
experi
diarrhea
advers
effect
daili
dose
reduc
mg
low
dose
take
longer
achiev
clinic
effect
cqhcq
contraind
patient
retinopathi
therapi
may
attempt
gradual
increas
dosag
patient
hypersensit
reaction
hcq
cq
rel
contraind
includ
neuromuscular
disord
myasthenia
gravi
psychos
patient
porphyria
cutanea
tarda
risk
hepat
usual
dosag
antimalari
drug
patient
dehydrogenas
defici
defici
hemolysi
rare
dosag
advis
prescrib
physician
decis
activ
assess
prior
begin
antimalari
drug
therapi
case
activ
assess
clinic
control
symptom
potenti
hemolyt
anemia
need
german
red
list
also
contain
follow
absolut
contraind
diseas
hematopoiet
system
pregnanc
nurs
combin
hepatotox
agent
combin
monoamin
oxidas
mao
inhibitor
use
also
limit
patient
sever
liver
kidney
dysfunct
psoriasi
discuss
text
acut
overdos
usual
occur
children
accident
suicid
attempt
singl
dose
mg
chloroquin
tablet
fatal
children
year
arrhythmia
cardiac
arrest
lead
death
thu
prescrib
cqhcq
tablet
must
kept
well
reach
small
children
given
cqhcq
accumul
deep
compart
drug
virtual
imposs
remov
system
complic
treatment
acut
cqhcq
intox
consider
patient
experi
unspecif
symptom
tabl
treatment
may
attempt
interv
dosag
reduct
side
effect
list
follow
mandat
stop
therapi
one
studi
one
two
patient
quinacrin
report
advers
effect
begin
therapi
daili
dose
mg
mild
revers
one
three
patient
complain
headach
dizzi
gastrointestin
symptom
diarrhea
loss
appetit
nausea
abdomin
cramp
symptom
disappear
spontan
reduc
dose
one
five
patient
discontinu
treatment
patient
report
persist
abdomin
cramp
diarrhea
symptom
effect
treat
antacid
antispasmod
challeng
retinopathi
definit
diagnosi
discuss
elsewher
still
criteria
diagnos
retinopathi
diagnosi
base
subject
assess
examin
physician
although
retin
damag
highli
unlik
ideal
bodi
weight
use
determin
maximum
daili
dose
see
ophthalmolog
examin
fundoscopi
vision
field
test
color
vision
test
amsler
grid
test
advis
begin
treatment
within
first
month
therapi
annual
control
control
patient
renal
liver
insuffici
baselin
examin
import
detect
central
red
scotoma
occur
healthi
popul
scotoma
also
occur
patient
system
lupu
result
vascul
patient
syndrom
diabet
care
surveil
essenti
suggest
dosag
exceed
well
older
patient
patient
continu
therapi
year
amsler
grid
test
month
figur
recommend
earli
detect
accord
british
recommend
ophthalmolog
examin
mandatori
hcq
maximum
daili
dosag
observ
clinic
control
regular
physician
appoint
ask
scintil
scotoma
poor
night
vision
difficulti
read
recogn
face
annual
vision
test
advis
consult
ophthalmologist
recommend
specif
problem
treatment
exceed
five
year
cq
deposit
cornea
anterior
stroma
visibl
use
slit
lamp
necessit
stop
treatment
less
common
hcq
vision
limit
condit
revers
discontinu
drug
small
number
patient
especi
take
higher
dosag
mgday
adolesc
accommod
disord
occur
result
direct
effect
chloroquin
smooth
muscl
ciliari
bodi
symptom
also
usual
resolv
spontan
therapi
continu
dosag
quinacrin
advers
ocular
effect
variou
skin
reaction
also
occur
hyperpigment
maculopapularlichenoidurticari
exanthem
exfoli
reaction
dress
syndrom
hypersensit
light
one
studi
report
hyperpigment
revers
yellowish
skin
discolor
patient
take
quinacrin
appear
conjunctiva
may
resembl
jaundic
normal
bilirubin
level
patient
may
blue
black
discolor
skin
nail
pigment
diminish
dose
reduc
disappear
therapi
stop
exanthem
report
patient
treat
malaria
prophylaxi
symptom
resolv
stop
therapi
treat
system
lupu
patient
mild
revers
dermat
second
world
war
lichenoid
dermat
reportedli
occur
malaria
prophylaxistherapi
daili
dose
mgdaili
mgdaili
small
number
patient
led
anhidrosi
skin
atrophi
alopecia
nail
chang
pigmentari
disord
antimalari
drug
known
occasion
exacerb
exist
psoriasi
psoriasi
contraind
cq
therapi
systemat
analysi
literatur
conclud
neither
evid
exacerb
psoriasi
patient
take
antimalari
drug
use
determin
individu
basi
normal
dosag
cqhcq
neg
effect
heart
case
report
howev
conduct
disord
cardiomyopathi
even
death
quinacrin
psycholog
stimul
improv
drowsi
higher
dosag
howev
discontinu
drug
within
week
revers
symptom
restless
insomnia
psychos
occur
blood
count
chang
aplast
anemia
leukopenia
agranulocytosi
hemolysi
rare
almost
alway
relat
defici
author
thu
recommend
routin
measur
enzym
other
believ
unnecessari
sinc
hemolyt
effect
chloroquin
minim
quinacrin
therapi
blood
differenti
perform
everi
month
drop
hemoglobin
reticulocyt
treatment
must
stop
accord
manufactur
inform
cqhcq
taken
pregnant
women
except
treat
malaria
isol
report
hear
loss
blind
birth
defect
spontan
abort
yet
harm
fetu
also
occur
lupu
flare
pregnanc
thu
decid
individu
basi
risk
associ
underli
diseas
altern
therapi
compar
potenti
side
effect
antimalari
therapi
sever
observ
studi
literatur
analys
report
hcq
may
safe
taken
pregnanc
one
prospect
random
control
studi
children
mother
lupu
treat
hcq
higher
apgar
score
anomali
addit
report
lupu
flare
compar
control
group
base
publish
report
especi
use
hcq
pregnant
women
drug
appear
safe
thu
also
recommend
use
pregnant
women
lupu
similarli
pharmacovigil
counsel
center
embryon
toxicolog
http
wwwembryotoxd
call
use
cqhcq
antirheumat
therapi
accept
exposur
cqhcq
thu
reason
termin
pregnanc
warrant
invas
diagnost
procedur
ultrasound
studi
may
perform
women
take
therapi
higher
dosag
order
confirm
normal
fetal
organ
develop
cqhcq
pass
mother
fetu
birth
also
detect
urin
infant
breastf
mother
take
drug
still
report
abnorm
associ
breastfeed
therapi
accord
embryotox
malaria
prophylaxi
therapi
mother
may
continu
breastfeed
usual
therapi
decis
whether
continu
breastfeed
made
individu
basi
base
publish
report
hcq
therapi
mother
consid
accept
healthi
infant
close
quinacrin
pass
mother
fetu
placenta
drug
administ
pregnant
nurs
women
despit
report
interfer
pregnanc
sever
studi
found
relev
hematolog
hepatotox
effect
antimalari
drug
maximum
daili
dosag
exceed
sinc
american
colleg
rheumatolog
explicitli
state
laboratori
studi
need
therapi
advis
howev
get
baselin
result
blood
differenti
liver
valu
start
antimalari
therapi
order
rule
patholog
chang
patient
take
quinacrin
blood
differenti
rare
aplast
anemia
assess
start
therapi
afterward
everi
month
later
everi
month
cqhcq
especi
effect
inflamm
associ
cutan
lupu
sever
report
shown
smoke
associ
develop
cutan
lupu
also
respons
rate
therapi
lower
smoker
one
patient
cutan
lupu
smoker
smoker
cutan
lupu
erythematosu
diseas
area
sever
index
clasi
score
compar
one
studi
found
discoid
skin
lesion
heal
spontan
patient
given
antimalari
therapi
heal
rate
studi
patient
dle
hcq
effect
placebo
month
year
verruc
hypertroph
plaqu
respond
well
antimalari
therapi
take
achiev
consist
plasma
concentr
recommend
therapi
administ
least
two
month
switch
smoker
shown
poorer
respons
treatment
quinacrin
mgdaili
take
effect
week
achiev
maximum
effect
week
lower
daili
dosag
take
longer
monotherapi
quinacrin
shown
lead
signific
mark
improv
treat
patient
literatur
therapi
appear
inadequ
week
treatment
discontinu
combin
anoth
medic
cq
hcq
combin
therapi
enhanc
effect
therapi
compar
monotherapi
random
studi
last
week
cutan
lupu
mg
hcq
equal
effect
mg
acitretin
respons
rate
associ
fewer
side
effect
literatur
case
seri
patient
lupu
pannicul
improv
take
antimalari
drug
addit
posit
result
case
report
also
individu
report
treatment
failur
improv
combin
therapi
consist
cqhcq
quinacrin
diltiazem
scle
report
respons
rate
scle
well
quinacrin
synergist
effect
studi
report
success
rate
antimalari
drug
therapi
patient
intermitt
cutan
lupu
drug
usual
take
week
begin
take
effect
possibl
lymphocyt
infiltr
skin
photosensit
lupu
erythematosu
variant
well
antimalari
drug
shown
effect
compar
agent
antimalari
agent
advantag
carri
lower
risk
cutan
liver
toxic
kidney
reaction
compar
immunosuppress
neither
risk
bone
marrow
suppress
opportunist
infect
base
result
systemat
review
antimalari
drug
inhibit
exacerb
longstand
sle
prolong
patient
surviv
risk
exacerb
diseas
time
higher
patient
take
placebo
given
cq
take
cq
vs
patient
take
placebo
corticosteroid
necessari
medium
level
evid
found
show
protect
effect
irrevers
organ
damag
thrombosi
loss
bone
mass
low
evid
level
report
favor
effect
blood
lipid
protect
osteonecrosi
reduct
sever
exacerb
adjuv
effect
remiss
nephriti
delay
develop
system
lupu
protect
effect
develop
cancer
addit
symptom
fatigu
weak
arthralgia
myalgia
seros
mucou
membran
ulcer
also
shown
improv
sle
patient
small
case
seri
also
report
synergist
effect
quinacrin
sle
thu
cqhcq
recommend
basic
treatment
major
sle
patient
never
given
alon
howev
patient
cardiac
lung
kidney
hematolog
vascularcentr
nervou
system
manifest
antimalari
drug
lead
improv
ra
half
patient
decreas
joint
swell
pain
improv
function
paramet
averag
month
treatment
patient
ra
combin
therapi
methotrex
sulfasalazin
hcq
reportedli
led
respons
rate
significantli
better
monotherapi
methotrex
respons
combin
therapi
sulfasalazinehcq
respons
rate
hcq
also
reduc
transaminas
elev
result
methotrex
acetylsalicyl
acid
base
case
report
experi
therapi
effect
rare
disord
pct
cqhcq
given
much
lower
dosag
usual
twice
weekli
mg
cq
mg
hcq
cq
may
given
monotherapi
pct
patient
normal
erythrocyt
hemoglobin
iron
level
patient
polyglobulia
elev
plasma
iron
level
combin
therapi
ie
begin
bloodlet
ml
everi
week
plu
cq
mgweekli
hcq
mgweekli
recommend
one
studi
report
averag
month
pct
resolv
treat
patient
observ
studi
pct
patient
result
biopsi
studi
show
improv
liver
morpholog
side
effect
rare
occur
proper
dosag
daili
dosag
mg
hand
trigger
potenti
fatal
porphyria
crisi
rare
diseas
occur
older
age
women
clinic
histolog
chronic
ulcer
stomat
resembl
lichen
planu
certain
immunolog
characterist
diseas
respond
topic
system
corticosteroid
respond
antimalari
agent
therapi
steroid
sometim
requir
patient
sarcoidosi
also
skin
involv
one
random
prospect
studi
patient
given
therapi
month
cq
relat
signific
improv
month
month
longer
differ
group
indic
cq
similar
corticosteroid
tend
suppress
diseas
rather
cure
one
patient
seri
skin
chang
resolv
patient
allow
therapi
discontinu
patient
improv
slightli
respond
patient
lung
involv
statu
lung
improv
cq
therapi
cutan
sarcoidosi
establish
method
pulmonari
sarcoidosi
seem
respond
better
steroid
therapi
indic
administ
cq
hcq
patient
sarcoidosi
chronic
disfigur
skin
lesion
progress
extracutan
lesion
patient
steroid
therapi
contraind
adjuv
therapi
steroid
treatment
continu
steroid
failur
hypercalcemia
sarcoidosi
lymphoma
shown
improv
hydroxychloroquin
therapi
patient
dermatomyos
whose
skin
lesion
heal
system
steroid
therapi
variou
case
seri
shown
give
cqhcq
alon
combin
quinacrin
lead
improvementh
also
appli
dermatomyos
children
two
studi
report
laboratori
chemic
paramet
esr
signific
reduct
igg
iga
improv
clinic
paramet
one
retrospect
analysi
patient
span
year
ocular
pain
improv
dryness
eye
cornea
integr
rose
bengal
test
improv
schirmer
test
improv
minut
oral
pain
dri
mouth
well
salivari
flow
whole
treat
patient
report
improv
discrep
seen
result
may
due
start
point
therapi
therapi
perhap
effect
given
inflammatori
stage
burn
stage
diseas
patient
polymorph
light
erupt
antimalari
drug
treatment
choic
two
control
studi
cqhcq
led
improv
toler
sunlight
moder
clinic
improv
signific
reduct
exanthem
clinic
improv
impress
treatment
therefor
recommend
patient
sever
diseas
failur
topic
steroidsprotect
measur
sunlight
failur
lack
feasibl
uv
harden
one
open
studi
last
month
eczema
improv
significantli
patient
given
cq
allow
system
steroid
therapi
discontinu
eight
patient
moder
improv
forc
discontinu
therapi
due
advers
effect
one
case
seri
patient
hcq
reportedli
effect
corticosteroid
yet
due
unforeseen
spontan
heal
difficult
unequivoc
assess
result
sever
case
report
one
larger
case
seri
cqhcq
use
pediatr
patient
reportedli
led
complet
resolut
gener
granuloma
anular
therapi
continu
week
clinic
resolut
patient
remain
year
afterward
one
patient
seri
oral
lichen
planu
improv
patient
given
hcq
pain
red
improv
month
took
month
eros
heal
heal
report
patient
cq
also
success
use
lichen
planu
lower
lip
form
lichen
planu
area
skin
typic
occur
middl
east
base
case
report
experi
author
appear
cqhcq
therapi
highli
effect
one
case
studi
report
lichen
planu
nail
symptom
manifest
year
earlier
regim
cq
symptom
disappear
ten
week
stop
therapi
condit
return
one
case
seri
patient
necrobiosi
lipoidica
improv
within
month
cqhcq
inhibit
thrombocyt
aggreg
one
studi
given
prevent
thrombosi
follow
hip
replac
surgeri
hydroxychloroquin
mgdaili
week
significantli
reduc
incid
pulmonari
embol
patient
anoth
studi
rate
venou
arteri
thromboembol
complic
reduc
even
sle
patient
phospholipid
antibodi
given
hcq
therapi
experienc
thromboembol
within
year
control
group
cqhcq
thu
given
primari
prevent
therapi
thromboembol
patient
sle
patient
exist
complic
anticoagul
recommend
instead
due
increas
ldl
receptor
inhibit
cholesterol
synthesi
liver
total
cholesterol
ldl
triglycerid
level
decreas
sle
patient
especi
concomit
steroid
therapi
chloroquin
reduc
blood
glucos
level
thu
act
side
effect
corticosteroid
use
chloroquinehydroxychloroquin
fallen
favor
due
sever
ocular
side
result
incorrect
dose
risk
may
minim
observ
follow
principl
incid
side
effect
depend
heavili
plasma
level
drug
turn
result
revers
diffus
cqhcq
deep
compart
antimalari
drug
store
adipos
tissu
thu
key
avoid
retinopathi
observ
maximum
recommend
daili
dosag
mgkg
chloroquin
ideal
bodi
weight
mgkg
hydroxychloroquin
especi
import
lighter
patient
especi
women
small
obes
patient
delay
elimin
due
renal
liver
dysfunct
dosag
reduc
ophthalmolog
control
first
month
therapi
advis
later
larger
interv
guidelin
follow
cqhcq
may
even
given
longer
period
time
minim
risk
none
correspond
prof
dr
med
falk
r
ochsendorf
klinik
dermatologi
venerologi
und
allergologi
klinikum
der
jw
frankfurt
main
tel
fax
ochsendorf
emunifrankfurtd
reichern
sich
zahlreichen
organenstrukturen
welchen
organenstrukturen
findet
kein
anreicherung
statt
epidermisb
dermisc
melanind
leber
welchen
stoffwechselweg
werden
cqhcq
vor
allem
ausgeschieden
im
stuhlb
nierenc
leberd
zu
gleichen
teilen
und
zu
gleichen
patient
soll
mit
chloroquin
behandelt
werden
er
wiegt
kg
bei
einer
von
cm
welchem
bereich
sollt
die
tagesdosi
liegen
mgb
mgc
mgd
mge
frau
soll
mit
hydroxychloroquin
behandelt
werden
sie
wiegt
kg
bei
einer
von
cm
welchem
bereich
sollt
die
tagesdosi
liegen
mgb
mgc
mgd
mge
standarddosi
von
quinacrin
mgb
mgc
mgd
mge
der
folgenden
faktoren
vermindert
die
klinisch
von
cqhcq
beim
kutanen
lupu
erythematod
besond
einnahm
von
cqhcq
mit
einer
mahlzeitb
komedik
mit
glucocorticoidenc
komedik
mit
methotrexatd
rauchen
vorhandensein
von
und
lang
muss
man
mindesten
warten
bi
man
den
effekt
einer
therapi
mit
antimalariamitteln
klinisch
beurteilen
kann
wochenb
wochenc
wochend
wochen
dosierung
von
chloroquin
verwendet
man
zur
therapi
der
porphyria
cutanea
tarda
bei
einem
cm
kg
schweren
mann
mgwocheb
mgwochec
mgdd
mgde
welcher
der
folgenden
sind
antimalariamittel
wenigsten
wirksam
polymorph
lichtdermatoseb
sarkoidosec
dermatomyositisd
chronisch
ulzer
vorgehen
ist
bei
einem
nicht
auf
ein
monotherapi
mit
chloroquin
ansprechenden
kutanen
lupu
erythematod
sinnvollsten
der
umstellung
auf
chloroquinc
umstellung
auf
quinacrind
kombin
mit
hydroxychloroquin
kombin
mit
quinacrin
lieb
leserinnen
und
leser
der
einsendeschluss
die
dda
dies
ausgab
ist
der
novemb
die
richtig
zum
thema
die
photodynamisch
therapi
der
dermatologi
heft
juni
ist
bitt
verwenden
sie
ihr
einsendung
da
aktuel
formblatt
auf
der
folgenden
seit
oder
aber
geben
sie
ihr
onlin
unter
http
jddgakademieddad
ein
